Our Mission
The ACC Nevada Chapter is dedicated to advancing the field of cardiovascular care through innovation, advocacy, and professional development, ensuring that Nevada’s clinicians are equipped to meet the evolving health challenges of our state.
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- ACCEL Lite: DAN-RSV: RSVpreF Vaccine for Preventing Cardiorespiratory HospitalizationsThe DAN-RSV trial is one of the largest individually randomized studies ever conducted, enrolling over 131,000 participants aged 60 and older to evaluate the effectiveness of the RSVpreF vaccine.
- New Insights Into Outcomes With Acoramidis in ATTR-CM, Danicamtiv in DCMResearch highlighting acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and danicamtiv for dilated cardiomyopathy (DCM) were presented during the Heart Failure Society of America (HFSA) 2025 meeting, held Sept. 26-29 in Minneapolis, MN, and simultaneously published in JACC.
- New ACC Scientific Statement Details Role of Inflammation in CVDA new ACC Scientific Statement on Inflammation and Cardiovascular Disease (CVD) highlights new groundbreaking research linking inflammation atherosclerotic cardiovascular disease (ASCVD) and provides consensus-based recommendations for evaluation, treatment and prevention reflecting this new era.
- ACC CardioSurve: Improved Education, Guidelines For Clinicians Could Boost Cardiogenetic TestingCardiogenetic testing could be more widely implemented if clinicians had improved access to genetic counselors and professionals, clearer guidelines and expanded education, according to a survey of the ACC CardioSurve Panel and published July 7 in JACC: Advances.
- FDA Update: Agency Approves Evinacumab-dgnb ANGPTL3 Antibody For Children With HoFHThe U.S. Food and Drug Administration (FDA) has approved evinacumab-dgnb ANGPTL3 antibody (Evkeeza®) to treat homozygous familial hypercholesterolemia (HoFH) in children as young as 1-year-old, according to a Regeneron® press release.